Granted Patent B2

US 12,343,319 · App. 18/652,721 · Granted Jul 1, 2025

Inventors: Carrie Bowen (Encinitas, CA); Glenn F. Short (Encinitas, CA); Thomas Cameron Robertson (Encinitas, CA)

Assignee: Atai Therapeutics, Inc.

A61K31/137A61P25/20A61P25/24

Abstract

Claims (24)

1. A method of treating a sleep dysfunction or a sleep disorder in a subject comprising administering to the subject a compound of Formula (I):

or a pharmaceutically acceptable salt thereof; wherein

R 1 is independently at each position hydrogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl;

R 2 , R 3 and R 7 are independently hydrogen, heterocycle, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, halogen, cyano, OR 1 , S(O)(=NH)R 1 , S(O) 2 R 1 , S(O)R 1 or SR 1 , wherein at least one of R 2 and R 3 is hydrogen;

R 4 , R 5 and R 6 are independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, halogen, cyano, OR 1 , SR 1 , (C═O)(R 14 ), O(C═O)(R 14 ), NO 2 , or NH(C═O)(R 14 ), wherein R 14 is C 1 -C 6 alkyl, OH, or OC 1 -C 6 alkyl;

R 8 and R 9 are independently hydrogen, C 1 -C 6 alkyl, C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 10 cycloalkyl, CH 2 OH, or CH 2 O—C 1 -C 4 alkyl;

R 10 and R 11 are independently hydrogen, halogen, C 1 -C 6 alkyl, OH, C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, or CH 2 O—C 1 -C 4 alkyl;

R 12 is hydrogen, CH 2 OH, CH 2 O—C 1 -C 9 alkyl, C 3 -C 10 cycloalkyl, CH 2 OH, or CH 2 O—C 1 -C 4 alkyl; and

R 13 is hydrogen, C 1 -C 9 alkyl, C 3 -C 10 cycloalkyl, CH 2 OH, or CH 2 O—C 1 -C 4 alkyl,

thereby treating the sleep dysfunction or the sleep disorder in the subject.

2. The method of claim 1 , wherein the sleep dysfunction or sleep disorder is a hypersomnia or a circadian rhythm sleep disorder.

3. The method of claim 2 , wherein the hypersomnia is narcolepsy, long sleeper disorder, Kleine-Levine Syndrome, or a combination thereof.

4. The method of claim 3 , wherein the hypersomnia is narcolepsy.

5. The method of claim 3 , wherein the hypersomnia is long sleeper disorder.

6. The method of claim 3 , wherein the hypersomnia is Kleine-Levine Syndrome.

7. The method of claim 2 , wherein the circadian rhythm sleep disorder is delayed sleep-wake phase disorder, advanced sleep-wake phase disorder, a non-24 sleep wake rhythm, or a combination thereof.

8. The method of claim 7 , wherein the circadian rhythm sleep disorder is delayed sleep-wake phase disorder.

9. The method of claim 7 , wherein the circadian rhythm sleep disorder is advanced sleep-wake phase disorder.

10. The method of claim 7 , wherein the circadian rhythm sleep disorder is a non-24 sleep wake rhythm.

11. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

12. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

13. The method of claim 1 , wherein the administering comprises sublingual, intracutaneous, subcutaneous, intramuscular, intraperitoneal, intravenous, intraarterial, intradermal, transdermal, oral, buccal, or nasal route of administration.

Assignments (1)

Continuity (4)

References Cited (165)